December 2022

Incorporated in 1996, SIRO Clinpharm Private Limited is a Clinical Research Organisation supporting trials from Phase II to Phase IV and beyond post-launch of products. SIRO offers a range of services, from clinical operations to data services, data analytics and medical writing in compliance with international standards.   SIRO has been an industry pioneer over two decades, sharing an incontestable record of excellence in the pharmaceutical, FMCG and medical device industry.

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.

Preventing metastasis – the development of cancer cells beyond their original location – remains one of the major goals of current cancer research. Most malignant tumor cells metastasize by exploiting abnormal leakage from blood vessels. New work looks to further explore the role of how the alignment of endothelial cells, which line blood vessels, plays a role in the spread of cancer.

Pfizer Inc and BioNTech SE announced that the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.

Union Minister of State (Independent Charge) Science & Technology, Dr Jitendra Singh said, India will make significant investment in R&D to develop a roadmap for design and delivery of vaccine development for future pandemic.

Our Educational Organization Maharishi Parshuram College of Pharmacy is a premier College in Fazilka Punjab (Running D-Pharmacy) with academic excellence Maharishi Parshuram College of Pharmacy is approved by AICTE, PCI New Delhi and Govt. of Punjab.

HOD/ Principal of Diploma Pharmacy College
Qualification – M.Pharma with 5 yrs experience 

Jawaharlal Nehru Centre for Advanced Scientific Research is an autonomous institution that was established in 1989 by the Department of Science and Technology, GoI to commemorate the birth centenary year of Pandit Jawaharlal Nehru. Bharat Ratna Prof. C. N. R. Rao, FRS, was the founding President. The Centre was registered as a society with Dr. Raja Ramanna (eminent physicist and Former Chairman, DAE) as its first Chairman.

Post : Research Associate

Advanced Centre for Treatment, Research and Education in Cancer, ACTREC, is a unique Institute under the wing of Tata Memorial Centre and a grant-in-aid Institution of the Department of Atomic Energy. ACTREC conducts a PhD program in Life Sciences that is affiliated with the Homi Bhabha National Institute (a deemed university under category A by MHRD, Govt. of India). Fulfilling its ‘bench-to- bedside’ mandate, the Institute provides a highly conducive environment for world-class cancer research.

The National Institute of Biologicals (NIB) had been set up in 1992. NIB is an apex autonomous institute under the administrative control of Ministry of Health & Family Welfare (MoHFW), Government of India. The Institute is performing primary statutory function of Quality Control of Biologicals e.g. Insulin, erythropoietin, blood products, diagnostic kits e.g. HIV, HBV, HCV, therapeutic monoclonal antibodies like Trastuzumab and Rituximab used in cancer treatment etc.